The 36-month beta value for IOVA is at 0.87. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for IOVA is 221.12M, and currently, shorts hold a 22.15% of that float. The average trading volume for IOVA on May 06, 2024 was 8.92M shares.
IOVA) stock’s latest price update
The stock of Iovance Biotherapeutics Inc (NASDAQ: IOVA) has increased by 5.82 when compared to last closing price of 12.88. Despite this, the company has experienced a 17.10% gain in its stock price over the last five trading sessions. The Motley Fool reported 2024-05-05 that Rocket Lab USA is in the right place at the right time with the right solution. The amount of digital data is exploding, and Confluent helps companies get a handle on this challenge.
IOVA’s Market Performance
Iovance Biotherapeutics Inc (IOVA) has seen a 17.10% rise in stock performance for the week, with a 0.22% gain in the past month and a 72.53% surge in the past quarter. The volatility ratio for the week is 5.99%, and the volatility levels for the past 30 days are at 5.34% for IOVA. The simple moving average for the last 20 days is 11.79% for IOVA stock, with a simple moving average of 63.63% for the last 200 days.
Analysts’ Opinion of IOVA
Many brokerage firms have already submitted their reports for IOVA stocks, with Goldman repeating the rating for IOVA by listing it as a “Buy.” The predicted price for IOVA in the upcoming period, according to Goldman is $12 based on the research report published on November 20, 2023 of the previous year 2023.
Barclays, on the other hand, stated in their research note that they expect to see IOVA reach a price target of $18, previously predicting the price at $40. The rating they have provided for IOVA stocks is “Overweight” according to the report published on September 18th, 2023.
Wells Fargo gave a rating of “Overweight” to IOVA, setting the target price at $17 in the report published on May 30th of the previous year.
IOVA Trading at -2.87% from the 50-Day Moving Average
After a stumble in the market that brought IOVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.64% of loss for the given period.
Volatility was left at 5.34%, however, over the last 30 days, the volatility rate increased by 5.99%, as shares surge +0.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.49% lower at present.
During the last 5 trading sessions, IOVA rose by +17.10%, which changed the moving average for the period of 200-days by +74.74% in comparison to the 20-day moving average, which settled at $12.20. In addition, Iovance Biotherapeutics Inc saw 67.65% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IOVA starting from Rothbaum Wayne P., who purchase 5,000,000 shares at the price of $9.15 back on Feb 20 ’24. After this action, Rothbaum Wayne P. now owns 28,067,333 shares of Iovance Biotherapeutics Inc, valued at $45,750,000 using the latest closing price.
MCPEAK MERRILL A, the Director of Iovance Biotherapeutics Inc, purchase 250,000 shares at $9.15 during a trade that took place back on Feb 20 ’24, which means that MCPEAK MERRILL A is holding 320,150 shares at $2,287,500 based on the most recent closing price.
Stock Fundamentals for IOVA
Current profitability levels for the company are sitting at:
- -387.35 for the present operating margin
- -21.01 for the gross margin
The net margin for Iovance Biotherapeutics Inc stands at -370.52. The total capital return value is set at -0.69. Equity return is now at value -81.91, with -61.49 for asset returns.
Based on Iovance Biotherapeutics Inc (IOVA), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -41.22. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is 132.12.
Currently, EBITDA for the company is -427.43 million with net debt to EBITDA at 0.09. When we switch over and look at the enterprise to sales, we see a ratio of 3175.01. The receivables turnover for the company is 7.87for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.79.
Conclusion
In conclusion, Iovance Biotherapeutics Inc (IOVA) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
